Can a tailored infusion schedule prevent fractures after stopping denosumab?

NCT ID NCT06767150

Recruiting now Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at women with postmenopausal osteoporosis who have been on denosumab for at least two years and are now stopping it. Stopping denosumab can cause a rapid bone loss and increase fracture risk. The trial compares two strategies using zoledronic acid infusions: one where the second infusion is given based on a blood test (crosslaps levels), and another where it is given at a fixed time. The goal is to see which approach better maintains bone density after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zoledronic acid (ZOL)
What this could lead to: If successful, this could provide a safer way to stop denosumab without losing bone density or increasing fracture risk.
What could go wrong: This is a small, early-phase trial with only 200 participants, so results may not apply to everyone. The personalized approach may not outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTMENOPAUSAL OSTEOPOROSIS

Contacts and locations

Locations

Amiens Hospital
RECRUITING

Amiens, France
Bordeaux Hospital
RECRUITING

Bordeaux, France
Cahors Hospital
RECRUITING

Cahors, France
Cochin Hospital
RECRUITING

Paris, France
Dax Hospital
RECRUITING

Dax, France
Lariboisiere Hospital
RECRUITING

Paris, France
Le Mans Hospital
RECRUITING

Le Mans, France
Lille Hospital
NOT_YET_RECRUITING

Lille, France
Limoges Hospital
RECRUITING

Limoges, France
Marseille Hsopital
RECRUITING

Marseille, France
Montpellier Hospital
RECRUITING

Montpellier, France
Nice Hospital
RECRUITING

Nice, France
Orléans Hospital
RECRUITING

Orléans, France
Poitiers Hospital
RECRUITING

Poitiers, France
Rennes Hospital
RECRUITING

Rennes, France
Saint Etienne Hospital
RECRUITING

Saint-Etienne, France
Toulouse Hospital
RECRUITING

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.